ERBB2 and pituitary tumor: Considering that we have previously reported that HN exerts a potent cytoprotective effect in pituitary tumor cells [15,18] and in HER2+ and triple-negative breast cancer cells [16], we assessed whether exogenous HN can also modulate the response of GBM cells to chemotherapy.